CL2012000631A1 - Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico. - Google Patents

Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico.

Info

Publication number
CL2012000631A1
CL2012000631A1 CL2012000631A CL2012000631A CL2012000631A1 CL 2012000631 A1 CL2012000631 A1 CL 2012000631A1 CL 2012000631 A CL2012000631 A CL 2012000631A CL 2012000631 A CL2012000631 A CL 2012000631A CL 2012000631 A1 CL2012000631 A1 CL 2012000631A1
Authority
CL
Chile
Prior art keywords
cdrs
sec
polynucleotide
diagnosis
kit
Prior art date
Application number
CL2012000631A
Other languages
English (en)
Inventor
Andreas Muhs
Andrea Pfeifer
Maria Pihlgren
Ryan Watts
Original Assignee
Ac Immune Sa
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Genentech Inc filed Critical Ac Immune Sa
Publication of CL2012000631A1 publication Critical patent/CL2012000631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 CDRS de cadena liviana (SEC Nº21/22/23) y los 3 CDRS de cadena pesada (SEC Nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnóstico; kit; y su uso terapéutico.
CL2012000631A 2007-06-12 2012-03-09 Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico. CL2012000631A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94354307P 2007-06-12 2007-06-12
US94354107P 2007-06-12 2007-06-12
US94379007P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
CL2012000631A1 true CL2012000631A1 (es) 2012-10-05

Family

ID=39790376

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008001742A CL2008001742A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
CL2012000631A CL2012000631A1 (es) 2007-06-12 2012-03-09 Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico.
CL2012001817A CL2012001817A1 (es) 2007-06-12 2012-07-04 Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2008001742A CL2008001742A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2012001817A CL2012001817A1 (es) 2007-06-12 2012-07-04 Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008).

Country Status (18)

Country Link
EP (2) EP2527366B1 (es)
JP (2) JP5436414B2 (es)
KR (2) KR20160017126A (es)
CN (1) CN101802007B (es)
AR (1) AR066987A1 (es)
AU (1) AU2008267037B2 (es)
BR (1) BRPI0812484A2 (es)
CA (1) CA2690434C (es)
CL (3) CL2008001742A1 (es)
ES (1) ES2548102T3 (es)
IL (1) IL202563A (es)
MX (1) MX2009013503A (es)
NZ (2) NZ581835A (es)
PE (2) PE20131141A1 (es)
RU (1) RU2571856C2 (es)
TW (2) TWI516500B (es)
WO (1) WO2008156621A1 (es)
ZA (1) ZA201000049B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
CN103443277B (zh) 2011-02-18 2016-02-24 国立大学法人东京农工大学 淀粉样蛋白低聚物结合核酸适体
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017184873A2 (en) * 2016-04-20 2017-10-26 Aelan Cell Technologies, Inc. Compositions and methods related to the methylation of histone h1.0 protein
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
AU2020347483A1 (en) * 2019-09-10 2022-03-31 Ac Immune Sa Novel molecules for diagnosis
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN110687035A (zh) * 2019-10-10 2020-01-14 沈阳万类生物科技有限公司 Annexin V-Light 650凋亡检测试剂盒
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
CN113308439B (zh) * 2020-11-06 2023-05-05 华中科技大学 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN119390832B (zh) * 2024-10-12 2026-06-09 中国科学技术大学 一种兔源Aβ 1-40单克隆抗体、制备方法及应用
CN120098147B (zh) * 2025-05-07 2025-07-15 中山大学 一种纳米自组装抗Aβ抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
DE69526973T3 (de) 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
EP1416280A3 (en) * 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1420032B2 (en) * 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
US7060270B2 (en) * 2001-11-02 2006-06-13 Diagenics International Corporation Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
WO2004065569A2 (en) * 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006121656A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
DK2594591T3 (en) * 2005-08-11 2018-07-30 Matossian Rogers Arpi TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody

Also Published As

Publication number Publication date
CN101802007A (zh) 2010-08-11
WO2008156621A1 (en) 2008-12-24
ZA201000049B (en) 2018-11-28
EP2170953A1 (en) 2010-04-07
ES2548102T3 (es) 2015-10-13
CL2008001742A1 (es) 2008-11-21
EP2527366A1 (en) 2012-11-28
JP2010530227A (ja) 2010-09-09
JP2014087353A (ja) 2014-05-15
IL202563A0 (en) 2011-08-01
TW200906852A (en) 2009-02-16
PE20090831A1 (es) 2009-07-10
NZ601843A (en) 2014-01-31
CA2690434C (en) 2018-05-22
TWI516500B (zh) 2016-01-11
CL2012001817A1 (es) 2012-12-14
CN101802007B (zh) 2017-08-25
EP2527366B1 (en) 2017-08-16
KR20160017126A (ko) 2016-02-15
MX2009013503A (es) 2010-01-27
AU2008267037B2 (en) 2014-08-07
IL202563A (en) 2016-05-31
NZ581835A (en) 2012-09-28
TWI453217B (zh) 2014-09-21
TW201441256A (zh) 2014-11-01
AR066987A1 (es) 2009-09-23
AU2008267037A1 (en) 2008-12-24
KR20100027216A (ko) 2010-03-10
HK1140500A1 (en) 2010-10-15
CA2690434A1 (en) 2008-12-24
EP2170953B1 (en) 2015-07-15
PE20131141A1 (es) 2013-10-14
BRPI0812484A2 (pt) 2018-06-05
KR101600095B1 (ko) 2016-03-07
RU2010100354A (ru) 2011-07-20
RU2571856C2 (ru) 2015-12-20
JP5436414B2 (ja) 2014-03-05

Similar Documents

Publication Publication Date Title
CR11658A (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
AR066170A1 (es) Anti integrina alfa 5 beta 1
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
CL2007000851A1 (es) Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
CL2011000851A1 (es) Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
CL2008001741A1 (es) Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
ECSP10010270A (es) Anticuerpos bivalentes biespecíficos
ECSP10010297A (es) Anticuerpos bivalentes biespecíficos
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
GT200900035A (es) Anticuerpo especifico prlr y sus usos
EA200970987A1 (ru) Трициклические азотсодержащие соединения в качестве антибактериальных агентов
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
CR11216A (es) Anticuerpos anti-cd79b e inmmunoconjugados y metodos de uso de los mismos
ECSP109940A (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso
MX2012009088A (es) Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
BRPI0510674A (pt) variantes fc otimizadas
UY33124A (es) Agentes y epítopos enlazados a wise
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CL2008001742A1 (es) Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.